Mitoxantrone Hydrochloride Liposome & Enlonstobart
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed or Refractory Peripheral T Cell Lymphoma
Conditions
Relapsed or Refractory Peripheral T Cell Lymphoma
Trial Timeline
Dec 8, 2025 → Dec 31, 2027
NCT ID
NCT07288814About Mitoxantrone Hydrochloride Liposome & Enlonstobart
Mitoxantrone Hydrochloride Liposome & Enlonstobart is a phase 1/2 stage product being developed by Sun Pharmaceutical for Relapsed or Refractory Peripheral T Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07288814. Target conditions include Relapsed or Refractory Peripheral T Cell Lymphoma.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed or Refractory Peripheral T Cell Lymphoma were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07288814 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Relapsed or Refractory Peripheral T Cell Lymphoma